Tigecycline: A Single Antibiotic for Polymicrobial Infections

Pankey, George A.; Steele, Russell W.

doi:10.1097/01.inf.0000253038.78188.26

Cited by 15 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It can be used to treat various aerobic and anaerobic Gram‐positive and Gram‐negative pathogens as well as atypical pathogens 3–9. It has been approved by the FDA for the treatment of complicated skin and skin–structure infections, complicated intra‐abdominal infections, and community‐acquired pneumonia 3–9. It has also been found to be generally safe and well tolerated in the treatment of secondary bacteremia 18.…”

Section: Discussionmentioning

confidence: 99%

“…Bacteremia poses a major risk to immunocompromised patients, especially when the causative organism is resistant to multiple antibiotics 2. Tigecycline, first member of the glycyclines, has in vitro activity against a wide variety of organisms, including multi‐drug‐resistant pathogens 1, 3–9. It can also be a good alternative for the treatment of infections caused by Corynebacterium .…”

Section: Introductionmentioning

confidence: 99%

“…It can also be a good alternative for the treatment of infections caused by Corynebacterium . However, it has not yet been approved for use in children 7, 10. In this report, we describe the case of a pediatric patient with relapsed and refractory acute lymphoblastic leukemia (ALL) whose Corynebacterium jeikeium infection was successfully treated with tigecycline without removal of the patient's central venous catheter (CVC).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tigecycline treatment of multi‐drug‐resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia

Dinleyici

Yargiç

Bör

et al. 2010

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Corynebacterium jeikeium has been recognized as an important cause of infection, particularly among neutropenic patients who have central venous catheter (CVC). Routine use of tigecycline in children is not yet approved. Here in we present a child with relapsed-refractory lymphoblastic leukemia who was successfully treated with tigecyline due to multi-drug-resistant C. jeikeium sepsis without removal of CVC. Our case highlights the use of tigecycline where there are no alternatives. Further studies regarding the efficacy and safety of tigecycline in pediatric patients are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tigecycline treatment of multi‐drug‐resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia

Dinleyici

Yargiç

Bör

et al. 2010

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Other potential adverse events include photosensitivity, pseudo tumor cerebri, pancreatitis and anti-anabolic effects. The dosage in children aged 12 years and older has been suggested as 1.5 mg/kg followed by 1 mg/kg (not to exceed 50 mg) every 12 hours [ 8 ]. In our case, we used half the adult dose, with no adverse effects and it was lifesaving.…”

Section: Discussionmentioning

confidence: 99%

Purulent Pericarditis with Quadruple Valve Endocarditis

et al. 2015

View full text Add to dashboard Cite

Patient: Male, 7Final Diagnosis: Purulent pericarditis with quadruple valve endocarditisSymptoms: —Medication: (4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]-4,7 bis(dimethylamino)-1,4,4a,5,5a,6,11,12aoctahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2 naphthacenecarboxamideClinical Procedure: PericardiocentisisSpecialty: CardiologyObjective:Rare diseaseBackground:Infective endocarditis (IE) is a disease with a highly varied clinical picture. Spread of the infection to the pericardium from the infective endocardium is uncommon and IE involving all 4 cardiac valves is also a very rare occurrence, being more common in intravenous drug users (IVDU).Case Report:A 7-year-old boy had purulent pericarditis with infective endocarditis (IE) on all 4 cardiac valves and vegetation in the left ventricular and right atrial cavity. Culture of the pericardial fluid grew methicillin-resistant staphylococcus aureus (MRSA) sensitive to tigecycline. The child made a dramatic improvement with tigecycline treatment.Conclusions:Aggressive management with pericardiocentesis and appropriate antibiotics can show remarkable clinical improvement. Tigecycline can be used safely and effectively as a life-saving drug in children.

show abstract

“…Patojenlerin direnç mekanizmalarının çoğundan etkilenmediğinden oldukça güçlü bir kemoterapötik ajandır. Komplike cilt-yumuşak doku enfeksiyonları (CYDE), komplike intra-abdominal enfeksiyonlar (İAE) ve toplum-aracılı pnömoni (TAP) tedavisi için yetişkinlerde onaylanmış olsa da, güvenliliği ve etkinliği ortaya koyulmadığından tigesiklinin 18 yaşından küçük hastalarda kullanımı tavsiye edilmemektedir (1,(4)(5)(6)(7). Ancak özellikle çoklu ilaç dirençli (ÇİD) ve yaygın ilaç dirençli (YİD) nozokomiyal gram-negatif bakterilere bağlı enfeksiyonlara sahip hastalar olmak üzere seçilmiş hastalarda tigesiklin kullanımı zorunlu olabilir (7,8).…”

Section: Introductionunclassified

Ciddi Hastalığı Olan Çocuklarda Tigesiklin Kurtarma Tedavisi

Kara¹,

Sütçü²,

Aktürk³

et al. 2018

J Pediatr Inf

View full text Add to dashboard Cite

Objective: Tigecycline has a wide spectrum antimicrobial activity including multi-drug resistant and extended drug resistant nosocomial Gram-negative bacteria. Although its pediatric use has not been approved, clinicians are sometimes obligated to choose tigecycline as salvage therapy. In this study, we present our clinical experience regarding tigecycline use in children. Material and Methods: This was a retrospective study of children who had been given tigecycline therapy at least 48 consecutive hours of duration in the pediatric departments of two tertiary-centers from January 2011 to March 2016. Results: Twenty four patients (13 female, 54.2%) with median age of 96 months (1-192) were enrolled. Tigecycline was started for ventilator associated pneumonia (n= 10, 41.7%), blood stream infection (n= 7, 29.2%), catheter related infection (n= 1, 4.2%), complicated skin soft tissue intection (n= 1, 4.2%) and emprically (n= 5, 20.8%). The most common isolated pathogen was Acinetobacter baumannii (n= 13, 54.2%). Other pathogens were Klebsiella spp. (n= 4, 16.6%), methicilline resistant Staphylococcus aureus, (n= 1, 42%) and Leptospira spp. (n= 1, 4.2%). All of the patients had tigecycline combination therapy. The most common combination was tigecycline + colistin (n= 10, 41.7%). Two patients (8.3%) had mild adverse events. The mortality rate was 45.8%. There was negative correlation between the age of patients and mortality rate (p= 0.006). Conclusion: Tigecycline may be used in critically ill children as salvage therapy with considerably mild side effects.

show abstract

Tigecycline: A Single Antibiotic for Polymicrobial Infections

Cited by 15 publications

References 9 publications

Tigecycline treatment of multi‐drug‐resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia

Tigecycline treatment of multi‐drug‐resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia

Purulent Pericarditis with Quadruple Valve Endocarditis

Ciddi Hastalığı Olan Çocuklarda Tigesiklin Kurtarma Tedavisi

Contact Info

Product

Resources

About